Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7295 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD7295 | DRUG | ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution |
| Placebo | DRUG | multiple ascending dose (tbd based on single dose results), oral solution |
Inclusion Criteria: * Provision of signed, written and dated informed consent * Healthy male Japanese volunteers aged 20-55 years * BMI between 18 and 27 kg/m2 * Have negative screens for HIV, hepatitis B and C viruses and syphilis Exclusion Criteria: * Use of prescribed medication within 2 weeks...
AZD7295 is an investigational small molecule being studied in healthy subjects. It is not approved for any disease and is in early clinical development. The completed Phase 1 trial evaluated its safety, tolerability, and pharmacokinetics in healthy Japanese male volunteers.
AZD7295 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company sponsored the Phase 1 clinical trial of this investigational small molecule.
AZD7295 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is no longer in active clinical testing.
AZD7295 has one completed Phase 1 trial, NCT00818129, which studied safety, tolerability, and pharmacokinetics following single and multiple ascending doses in healthy Japanese male subjects. The trial enrolled 62 participants and was placebo-controlled and double-blind.
No alternative names for AZD7295 have been reported. It is identified by its code name AZD7295 in clinical trial records and is not known to be marketed under any other brand name.